4.39
price up icon12.85%   0.50
after-market After Hours: 4.28 -0.11 -2.51%
loading
Longeveron Inc stock is currently priced at $4.39, with a 24-hour trading volume of 7.64M. It has seen a +12.85% increased in the last 24 hours and a +142.54% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.21 pivot point. If it approaches the $4.62 resistance level, significant changes may occur.
Previous Close:
$3.89
Open:
$3.98
24h Volume:
7.64M
Market Cap:
$42.15M
Revenue:
$709.00K
Net Income/Loss:
$-21.41M
P/E Ratio:
-4.6211
EPS:
-0.95
Net Cash Flow:
$-19.70M
1W Performance:
+153.76%
1M Performance:
+142.54%
6M Performance:
-61.83%
1Y Performance:
-86.64%
1D Range:
Value
$3.83
$4.615
52W Range:
Value
$0.7707
$37.50

Longeveron Inc Stock (LGVN) Company Profile

Name
Name
Longeveron Inc
Name
Phone
305-302-7158
Name
Address
1951 NW 7TH AVENUE, MIAMI
Name
Employee
24
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
LGVN's Discussions on Twitter

Longeveron Inc Stock (LGVN) Financials Data

Longeveron Inc (LGVN) Revenue 2024

LGVN reported a revenue (TTM) of $709.00 thousand for the quarter ending December 31, 2023, a -41.98% decline year-over-year.
loading

Longeveron Inc (LGVN) Net Income 2024

LGVN net income (TTM) was -$21.41 million for the quarter ending December 31, 2023, a -13.69% decrease year-over-year.
loading

Longeveron Inc (LGVN) Cash Flow 2024

LGVN recorded a free cash flow (TTM) of -$19.70 million for the quarter ending December 31, 2023, a -32.86% decrease year-over-year.
loading

Longeveron Inc (LGVN) Earnings per Share 2024

LGVN earnings per share (TTM) was -$10.20 for the quarter ending December 31, 2023, a -13.33% decline year-over-year.
loading
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
$152.17
price up icon 1.11%
$85.02
price up icon 1.32%
$27.05
price up icon 3.09%
$84.95
price up icon 0.30%
$466.42
price up icon 1.02%
$260.51
price down icon 0.20%
Cap:     |  Volume (24h):